February 11, 2020
Eisai, Inc.’s partnership with Merck has proven to be successful with the FDA approval of the Keytruda and Lenvima Combination Treatment. With 13 indications for Lenvima and a robust oncology pipeline, Eisai, Inc. is the fastest-growing company in the area of oncology. To continue building upon their success and to meet the medical needs of patients and their families, Eisai, Inc. has retained The Chase Group to identify a new Executive Medical Director of New Products for their US Oncology Medical Affairs team. This new role reports directly to the Vice President of US Oncology Medical Affairs and requires an ambitious and passionate executive who will be responsible for driving and creating the US medical affairs strategy for launching these new indications. For more information, please contact moira@chasegroup.com
